Kelun-Biotech publishes phase III data for trastuzumab botidotin in HER2-positive breast cancer

AstraZeneca's Etcamah misses primary endpoint in Phase III breast cancer trial

GSK reports positive Jideytro data supporting potential first-line lung cancer use

Akeso presents positive results from registrational Phase III study of ivonescimab

ABL Diagnostics files bid to acquire IntegraGen

Tyra Biosciences declares positive Phase 2 results for oral dabogratinib in bladder cancer

Harbour BioMed partner raises USD225m to advance neoadjuvant immuno-oncology therapy porustobart

Kazia Therapeutics doses first patient in paediatric AT/RT study

Etcamah–CDK4/6 inhibitor combination approved in US for ESR1-mutated HR-positive breast cancer

Guardant Health wins FDA approval for Guardant360 CDx in advanced breast cancer

4basebio announces expansion of DNA offering for personalised mRNA medicines

Cipla partners with Qilu Pharmaceutical for licensing and supply of Keytruda biosimilar in US

Akeso's ivonescimab meets overall survival endpoint in interim analysis of Phase III HARMONi-2 study

AstraZeneca completes global licence agreement for Zegfrovy

AstraZeneca and Daiichi Sankyo's Enhertu plus pertuzumab approved in EU for first-line HER2-positive metastatic breast cancer